Sanofi announced today the immediate adoption of influenza strains selected by the US Food and Drug Administration (FDA) to advance the manufacturing and delivery of its vaccine portfolio for the 2025 ...

Sanofi adopts US FDA-selected flu strains to ensure readiness for the 2025-26 flu season: Bridgewater, New Jersey Monday, March 17, 2025, 14:00 Hrs [IST] Sanofi announced the imme ...

Sanofi (SNY) announced the immediate adoption of influenza strains selected by the Food and Drug Administration to advance the manufacturing ...

Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.

The last few years have been tough for the insulin market, with recent policies and high-level pressure forcing companies to ...

One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...

Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid ...

Sanofi licensed the antibody from Alopexx Pharmaceuticals, a precursor to the current biotech of the same name, in 2009 but faced challenges such as the slow enrollment (PDF) of a phase 2a trial.

This investment reaffirms the industry’s confidence in Enveda’s groundbreaking drug discovery platform and its ability to deliver differentiated medicines. Sanofi’s addition to the Series C ...

Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three ...

Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...

Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and pharmaceutical companies.